Guideline | Version | Date of publication | RIGHT Statement domain | Total score (%) (n=35) | |||||
Basic information (n=6) | Background (n=8) | Evidence (n=5) | Recommendations (n=7) | Review and quality assurance (n=2) | Funding and interests (n=4) | ||||
Acute lymphoblastic leukaemia | 1.2018 | 3/12/2018 | 4.0 | 6.5 | 1.5 | 3.5 | 1.0 | 4.0 | 21 (60.0) |
Acute myeloid leukaemia | 1.2018 | 2/7/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Amyloidosis | 1.2018 | 11/3/2017 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
Anal | 1.2018 | 2/6/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
B cell | 2.2018 | 2/26/2018 | 4.0 | 6.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
Basal cell | 1.2018 | 9/18/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Bladder | 3.2018 | 3/14/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Bone | 1.2018 | 8/29/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Breast | 4.2017 | 2/7/2018 | 4.5 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20 (57.1) |
Cervical | 1.2018 | 3/20/2018 | 4.0 | 4.5 | 1.5 | 3.5 | 1.0 | 4.0 | 19 (54.3) |
Chronic lymphocytic leukaemia | 1.2018 | 10/25/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Chronic myeloid leukaemia | 4.2018 | 3/14/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Central nervous system | 4.2018 | 1/24/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
Colon | 2.2018 | 3/14/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
Cutaneous B cell | 1.2018 | 9/18/2017 | 4.0 | 3.5 | 1.5 | 3.5 | 1.0 | 4.0 | 18 (51.4) |
Dermato-protuberans | 1.2018 | 3/16/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Esophageal | 1.2018 | 3/16/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Gastric | 2.2018 | 9/26/2017 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
Hairy cell | 1.2018 | 2/15/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
Head/neck | 1.2018 | 2/14/2018 | 4.0 | 4.0 | 1.5 | 3.5 | 1.0 | 4.0 | 18.5 (52.9) |
Hepatobiliary | 1.2018 | 12/20/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Hodgkin | 3.2018 | 2/6/2018 | 4.0 | 5.5 | 1.5 | 3.5 | 1.0 | 4.0 | 20 (57.1) |
Kaposi | 2.2018 | 2/26/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Kidney | 2.2018 | 1/19/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Myelodysplastic syndrome | 1.2018 | 9/18/2017 | 4.5 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20 (57.1) |
Melanoma | 4.2018 | 2/12/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
Merkel | 2.2018 | 2/15/2018 | 4.5 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20 (57.1) |
Mesothelioma | 2.2018 | 9/7/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Myeloproliferative Neoplasms | 3.2017 | 6/13/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Myeloma | 3.2018 | 2/21/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7%) |
Neuroendocrine | 1.2018 | 11/9/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Non-small-cell lung | 2.2018 | 3/9/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Occult primary | 3.2017 | 9/11/2017 | 4.0 | 5.5 | 1.5 | 3.5 | 1.0 | 4.0 | 20 (57.1) |
Ovarian | 1.2018 | 1/8/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Pancreatic | 2.2018 | 1/10/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Penile | 2.2018 | 3/8/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
Prostate | 1.2018 | 3/14/2018 | 4.0 | 6.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
Rectal | 2.2018 | 1/17/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Sarcoma | 1.2018 | 10/31/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Squamous cell | 2.2018 | 10/5/2017 | 4.5 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20 (57.1) |
Small-cell lung | 1.2018 | 9/6/2017 | 4.0 | 4.0 | 1.5 | 3.5 | 1.0 | 4.0 | 18.5 (52.9) |
T cell | 3.2018 | 2/22/2018 | 5.0 | 6.0 | 1.5 | 3.5 | 1.0 | 4.0 | 21.5 (61.4) |
Testicular | 2.2018 | 2/16/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Thymus | 2.2018 | 2/16/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
Thyroid | 2.2017 | 5/17/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Uterine | 1.2018 | 10/13/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
Vulvar | 1.2018 | 10/27/2017 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
Waldenstrom | 1.2018 | 3/7/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
NCCN, National Comprehensive Cancer Network; RIGHT, Reporting Items for practice Guidelines in HealThcare.